当前位置: X-MOL首页全球导师 国内导师 › 徐波

个人简介

学习经历 1.1998/10-2002/08 美国 St Jude 儿童研究医院 博士后 2.1995/09–1998/05 协和医科大学 博士 3.1992/09–1995/07 天津医科大学 硕士 4.1985/09–1990/07 白求恩医科大学 学士 工作经历 1.2020/04-至今 重庆大学附属肿瘤医院 院长;重庆大学弘深杰出教授 2.2016/11-2020/04 天津医科大学肿瘤医院 副院长/国家特聘教授 3.2012/08-2016/11 美国南方研究院/阿拉巴马大学医学院 系主任/杰出研究员/教授 4.2009/08-2012/08 美国康奈尔大学医学院附属卫理教会医院 资深研究员/教授/主任 5.2006/06-2009/08 美国南方研究院/阿拉巴马大学医学院 高级研究员/副教授 6.2002/08-2006/05 美国路易斯安娜州立大学 助理教授(tenure track) 7.1990/07-1995/08 天津医科大学总医院 医师/总住院医师 徐波教授全职回国前长期任美国南方研究院肿瘤学杰出研究员、系主任(Distinguished Fellow and Chairman)以及美国阿拉巴马大学伯明翰分校病理系教授。担任国家自然科学基金重点项目及面上项目课题评审委员,国家教育部长江学者评审委员,美国国立卫生研究院科研基金评审委员,美国国防部乳腺癌研究项目课题评审委员,意大利卫生部科研课题评审专家组成员等。在美期间任美国国立癌症研究所 (NCI)化学生物学中心 (CBC)执行委员会委员,南方研究院CBC中心共同主任,美国放射学院放射肿瘤学住院医师执业医师考核委员。作为课题负责人共获得美国联邦课题资助8项,研究经费超过八百万美元,包括两项R01,一项P20,一项R21,以及多项其它NIH及DoD课题。2016年8月以后以课题负责人获科技部重大专项精准医疗专项(2016YFC0904601)支持及两项国家自然科学基金(面上项目81672743 and 81974464)支持,2018年起以方向负责人承担国家“双一流”学科建设项目“乳腺癌的基础与临床研究”。2000年来在国际权威学术杂志 (包括《Nature》、《 Cell》、《 Molecular Cell》、《 Genes and Development》,《Nucleic Acids Research》, 《Clinical Cancer Research》等发表论文70余篇,其中关于DNA损伤后细胞周期监测点信号传导通路系列文章至今已被引用7500余次并得到国际同行的一致认可,共有6篇被 Faculty 1000推荐。 在基础研究方面,他带领的团队建立了一系列方法去研究DNA损伤后蛋白之间的相互作用及信号传导通路,在同行中得到广泛应用。在转化医学研究方面,他在国际上提出采用融合多肽靶向DNA损伤修复信号传导通路的策略以探索新型抗肿瘤药物及放化疗增敏药物,获国际专利2项。他提出的高通量法筛选小分子化合物抑制蛋白与蛋白之间的功能链接得到美国国立卫生研究院路线图项目(Roadmap Initiatives)的资助。2017年推出国际首例多肽型PDL1免疫检测点抑制剂。徐波教授重视医工交叉学科对肿瘤学的重要推动作用,提出智能肿瘤学的概念,2019年当选为中国抗癌协会肿瘤人工智能专业委员会首任主任委员。2019年牵头召开了首届智能肿瘤学全国论坛。团队在乳腺癌人工智能技术的应用研究在中央电视台《经济半小时》、《光明日报》及《科技日报》进行了专题报道。在鼻咽癌远地转移预后判断的AI判断系统已申请相关专利2项。申请人在新冠肺炎疫情期间与国家超级计算天津中心天河计算机平台合作在国际上首先建立人工智能结合CT影像辅助诊断新冠肺炎系统并取得了良好的预测效果。

研究领域

一直从事肿瘤学基础及转化医学方面的前沿研究,研究范围涵盖DNA损伤修复机制、基因组学、分子靶向抗肿瘤药物研发以及肿瘤人工智能的应用。

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

代表性文章 1. Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH, Kastan MB. Atm phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404: 613-617; 2000. Faculty of 1000 Prime recommended 2. Xu B, Kim ST and Kastan MB. Involvement of Brca1 in S-phase and G2-phase checkpoint after ionizing irradiation Molecular and Cellular Biology 21:3445-3450; 2001. Faculty of 1000 Prime recommended 3. Kim ST, Xu B (co-first author) and Kastan MB. Involvement of the Cohesin Protein, Smc1, in ATM–Dependent and–Independent Responses to DNA Damage. Genes & Development 16: 560-570, 2002. Faculty of 1000 Prime recommended 4. Xu B, Kim St, Lim DS, Kastan MB. Two Molecularly Distinct G2/M checkpoints Are Induced by Ionizing Irradiation Molecular and Cellular Biology 22 (4): 1049-1059; 2002. 5. Taniguchi T, Garcia-Higuera I, Xu B, Anderson P, Gregory R, Lane W, Kim S, Kastan MB, D’Andrea A. Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways. Cell 109: 459-472, 2002. Faculty of 1000 Prime recommended 6. Xu B, O’Donnell AH, Kim ST, Kastan MB. Phosphorylation of Serine 1387 in Brca1 is specifically required for the Atm-Mediated S-phase Checkpoint after Ionizing Irradiation. Cancer Research. Aug 15; 62(16):4588-91, 2002. 7. Garg, R., Geng, C.-D., Miller, J. L., Callens, S., Tang, X., Appel, B., Xu, B.* Molecular Cloning and Characterization of the Catalytic Domain of Zebrafish Homologue of the Ataxia-Telangiectasia Mutated Gene. Molecular Cancer Research 2: 348-353, 2004. Also featured the cover page of the issue. 8. Garg, R., Callens, S., Lim, D.-S., Canman, C. E., Kastan, M. B., Xu, B*. Chromatin Association of Rad17 Is Required for an Ataxia Telangiectasia and Rad-Related Kinase-Mediated S-Phase Checkpoint in Response to Low-Dose Ultraviolet Radiation. Molecular Cancer Research 2: 362-369, 2004. 9. Xu B*, Kastan MB. Analyzing cell cycle checkpoints after ionizing radiation. Methods Mol Biol.; 281: 283-92, 2004 10. Arlt, M. F., Xu, B., Durkin, S. G., Casper, A. M., Kastan, M. B., Glover, T. W.BRCA1 Is Required for Common-Fragile-Site Stability via Its G2/M Checkpoint Function. Molecular and Cellular Biology 24: 6701-6709, 2004. 11. Wakeman TP, Kim WJ, Callens S, Chiu A, Brown KD, Xu B*. The ATM-SMC1 Pathway is Essential for Activation of the Chromium [VI]-induced S-Phase Checkpoint. Mutation Research, 554(1-2):241-51, 2004. 12. Timothy Wakeman, Dorota Wyczechowska, and Bo Xu*. Involvement of the p38 MAP kinase in chromium-induced growth arrest and apoptosis. Mol Cell Biochem. 2005 Nov; 279(1-2):69-73 13. Timothy Wakeman, Renu Garg, and Bo Xu*, ATR regulates Cr-induced S-phase checkpoint through dissociation from Rad17. Mutation Research 2006 Nov 7; 610(1-2):14-20. 14. Mickael Cariveau, Jessie Tang, Xiaoli Cui, and Bo Xu*. Conserved NBS1 C-terminal small peptides can inhibit the ATM-mediated DNA damage response and enhance radiation sensitivity. Molecular Pharmacology, AUG 2007, 72(2): 320-326. 15. Mickael J. Cariveau, Murray Stackhouse, Xiao-li Cui, Kamal Tiwari, William Waud, John A. Secrist III, Bo Xu*. Clofarabine acts synergistically with ionizing radiation in vitro and in vivo by interfering with the DNA damage response, International Journal of Radiation Oncology, Biology, Physics, 2008, 70: 213-220 16. Xi Tang, Zhou-guang Hui, Xiao-li Cui, Renu Garg, Michael B. Kastan, and Bo Xu*. A novel ATM-dependent pathway regulates Protein Phosphatase 1 and histone H3 phosphorylation in response to DNA damage. Molecular Cellular Biology April 4, 2008, 2559-2566, Faculty of 1000 Prime recommended 17. Zhang C, Kang C, Wang P, Cao Y, Lv Z, Yu S, Wang G, Zhang A, Jia Z, Han L, Yang C, Ishiyama H, Teh BS, Xu B*, Pu P. (co-corresponding authors). MicroRNA-221/-222 regulate radiation sensitivity by targeting the PTEN pathway, International Journal Of Radiation Oncology, Biology and Physics, 2011 May 1;80(1):240-8. 18. Chunying Yang, ,Xi Tang, Xiaojing Guo, Yohei Niikura, Katsumi Kitagawa,Kemi Cui, Stephen T.C. Wong, Li Fu, and Bo Xu*. Aurora-B Mediated ATM Serine 1403 Phosphorylation Is Required For Mitotic ATM Activation and theSpindle Checkpoint. Molecular Cell. 44, 597-608 November 18, 2011. (appeared as issue highlights, article previewed, top-read, and Faculty of 1000 Prime recommended) 19. Chunying Yang, Haibo Wang, Yiran Xu, Kathryn Brinkman, Stephen Wong and Bo Xu*. The kinetochore protein Bub1 is required for DNA damage responses. DNA Repair 2012 Feb 1; 11(2):185-91. Epub 2011 Nov 9. 20. Mianen Sun, Xiaojing Guo, Chunying Yang, Kathryn Brinkman, David Engler, Binhua Zhou, Li Fu, Bo Xu*. Activation of the ATM-Snail pathway promotes breast cancer metastasis, Journal Of Molecular Cell Biology, 2012 Oct;4(5):304-15 21. Xiaonan Sun, Chunying Yang, Hai Liu, Wang Qi, Shi-Xiu Wu, Xia Li, Tian Xie, Kathryn, L. Brinkman, Bin S. Teh, E. Brain Butler, Bo Xu* and Shu Zheng*. Identification and Characterization of a Small Inhibitory Peptide that can Target DNA-PKcs Autophosphorylation and Increase Tumor Radiosensitivity. International Journal of Radiation Oncology, Biology and Physics. 2012 May 15, 84 (5), 1212-1219 22. Chun-ying Yang , Mike Lee, Jessie Tang, Xiaoli Cui, Paula Allen, Françoise Bontemps, William B. Parker, and Bo Xu*. Deoxycytidine kinase regulates the G2M checkpoint through interaction with Cyclin-Dependent Kinase 1 in response to DNA damage. Nucleic Acids Research, 2012 July 31. 40 (19), 9621-9632 23. Boohaker, R.; Cui, X.; Stackhouse, M.; Xu, B. ATM-mediated Snail Serine 100 Phosphorylation Regulates Cellular Radiosensitivity. Radiotherapy and Oncology. 7-25-2013. 24. Xiaojing Guo , Chunying Yang , Xiaolong Qian , Ting Lei , Yaqing Li , Haifa Shen , Li Fu and Bo Xu*. Estrogen Receptor Alpha regulates ATM expression through miRNAs in breast cancer, Clinical Cancer Research, Published Online First July 15, 2013; doi:10.1158/1078-0432.CCR-12-3700 25. Boohaker, R.; Xu B*. The Versatile functions of the ATM Kinase. Biomedical Journal 2014 Jan-Feb;37(1):3-9. 26. Zhang, D.; Wang, H.; Sun, M.; Yang, J.; Zhang, W.; Han, S.; Xu, B*. Speckle-type POZ protein, SPOP, is involved in the DNA damage response. Carcinogenesis. 2014 Aug;35(8):1691-7 27. Chunying Yang, Xiaojing Guo, Haibo Wang, David Engler, Wei Zhang, and Bo Xu*. Mad1 Serine 214 phosphorylation is critical for its role in mitotic spindle checkpoint activation. Carcinogenesis. 2014, Sep; 35(9):2007-13. 28. 54.Rebecca J Boohaker, Bo Xu, The Role of MicroRNAs in Modulating Tissue Response to Radiation, in Strategies to Enhance the Therapeutic Ratio of Radiation as a Cancer Treatment, Springer Nature press 2016 29. Nathaniel H. Boyd, M.S.1*, Kiera Walker, M.A.1*, Joshua Fried, B.S.2, James R. Hackney, M.D.3, Paul C. McDonald, Ph.D.4, Gloria A. Benavides, Ph.D.5, Raffaella Spina, Ph.D.6, Alessandra Audia, Ph.D.7, Sarah E. Scott1, Catherine J. Libby, B.S.1, Anh Nhat Tran, B.S.1, Mark O. Bevensee, Ph.D.1, Corinne Griguer, Ph.D.8, Susan Nozell, Ph.D.9, G. Yancey Gillespie, Ph.D.8, Burt Nabors, M.D.10, Krishna P. Bhat, Ph.D.7, Eli E. Bar, Ph.D.6, Victor Darley-Usmar, Ph.D.5, Bo Xu, M.D., Ph.D.2, Emily Gordon, Ph.D. 11, Sara J. Cooper,Ph.D.11, Shoukat Dedhar, Ph.D.4, Anita B. Hjelmeland, Ph.D.1 Addition of Carbonic Anhydrase 9 Inhibitor SLC-0111 to Temozolomide Treatment Delays Glioblastoma Growth in Vivo, Journal of Clinical Investigation (JCI) Insights, 2017;2(24):e92928. https://doi.org/10.1172/jci.insight.92928. 30. Wei X, Fried J, Li Y, Hu L, Gao M, Zhang S, Xu B. Functional roles of Speckle-Type Poz (SPOP) Protein in Genomic stability. J Cancer. 2018 Sep 7;9(18):3257-3262. doi: 10.7150/jca.25930. 31. Boohaker RJ, Sambandam V, Segura I, Miller J, Suto M, Xu B. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction. Cancer Lett. 2018 Oct 10;434:11-21. doi: 10.1016/j.canlet.2018.04.031. Epub 2018 Jun 18. 32. Wei X, Cai S, Boohaker RJ, Fried J, Li Y, Hu L, Pan Y, Cheng R, Zhang S, Tian Y, Gao M, Xu B.,KAT5 promotes invasion and metastasis through C-MYC stabilization in ATC. Endocrine Related Cancer. 2019 Jan 1;26(1):141-151. doi: 10.1530/ERC-18-0193. 33. Ying Y, Wang Y, Huang X, Sun Y, Zhang J, Li M, Zeng J, Wang M, Xiao W, Zhong L, Xu B, Li L, Tao Q, Wang X, Shu XS Oncogenic HOXB8 is driven by MYC-regulated super enhancer and potentiates colorectal cancer invasiveness via BACH1.Oncogene. 2019 Oct 7. doi: 10.1038/s41388-019-1013-1 34. Zhao Z, Li L, Du P, Ma L, Zhang W, Zheng L, Lan B, Zhang B, Ma F, Xu B, Zhan Q, Song Y. Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer. Theranostics. 2019 Feb 20;9(5):1401-1416. doi: 10.7150/thno.30701.

学术兼职

学术兼职 中国抗癌协会肿瘤人工智能专业委员会主任委员 中国抗癌协会第八届理事会理事 教育部乳腺癌防治重点实验室常务副主任 Radiotherapy and Oncology 编委 Biomedical Journal 编委

推荐链接
down
wechat
bug